
Rapport Therapeutics
Precision medicines to match the complexity of the human brain.
Series B+ ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredSep 23, 2022 (4 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | fundraisingfox.com |
Timeline
- Website created
Founders and team
DB
David Bredt Founder, Chief Scientific Officersource: rapportrx.com
Companies like Rapport Therapeutics
TTriGemX Bio$94M · Oct 2026
WWholenessSeed · Nov 2024PPrecision Neuroscience$250M Series B+ · Sep 2026
CCircular Genomics$15M Series A · Dec 2025
NNewronika$15.88M Series B+ · Feb 2025
NNeuralight$25M Series A · May 2022
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/rapport-therapeutics (get a free API key).